These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23452882)

  • 1. Not just numbers, but years of science: putting the ACE inhibitor-ARB meta-analyses into context.
    Ferrari R; Rosano GM
    Int J Cardiol; 2013 Jun; 166(2):286-8. PubMed ID: 23452882
    [No Abstract]   [Full Text] [Related]  

  • 2. ONTARGET still OFF-TARGET?
    Lambers Heerspink HJ; de Zeeuw D
    Circulation; 2011 Mar; 123(10):1049-51. PubMed ID: 21357820
    [No Abstract]   [Full Text] [Related]  

  • 3. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials.
    Tocci G; Paneni F; Palano F; Sciarretta S; Ferrucci A; Kurtz T; Mancia G; Volpe M
    Am J Hypertens; 2011 May; 24(5):582-90. PubMed ID: 21331058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
    Böhm M; Baumhäkel M; Mahfoud F; Werner C
    Cardiology; 2010; 117(3):163-73. PubMed ID: 21051889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The clinical usefulness of RAAS inhibitors in hypertensive patients].
    Yamaguchi K; Sata M
    Nihon Rinsho; 2012 Sep; 70(9):1571-6. PubMed ID: 23012805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema.
    Beavers CJ; Dunn SP; Macaulay TE
    Ann Pharmacother; 2011 Apr; 45(4):520-4. PubMed ID: 21427294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials.
    McAlister FA;
    Eur Heart J; 2012 Feb; 33(4):505-14. PubMed ID: 22041554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review.
    Ferrari R; Boersma E
    Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):705-17. PubMed ID: 23750680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus. A meta-analysis].
    Divisón Garrote JA; Seguí Díaz M; Escobar Cervantes C
    Semergen; 2014 Oct; 40(7):399-400. PubMed ID: 25103068
    [No Abstract]   [Full Text] [Related]  

  • 10. Blockers of the renin-angiotensin-aldosterone system: almost, but not yet, an absolute weapon against cardiovascular and renal diseases!
    Waeber B
    J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):216. PubMed ID: 22389390
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cardiovascular outcomes in chronic dialysis patients: a population-based cohort study.
    Bajaj RR; Wald R; Hackam DG; Gomes T; Perl J; Juurlink DN; Manno M; Garg AX; Kitchlu A; Mamdani MM; Yan AT
    Arch Intern Med; 2012 Apr; 172(7):591-3. PubMed ID: 22493468
    [No Abstract]   [Full Text] [Related]  

  • 12. [Anti-hypertensive treatment in metabolic syndrome--focus on ARB or ACE inhibitor].
    Yano Y; Kario K
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():576-81. PubMed ID: 21766663
    [No Abstract]   [Full Text] [Related]  

  • 13. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C
    Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of dementia by ACE inhibitors and angiotensin receptor blockers - potential but not proven.
    Todd S; McGuinness B; Passmore AP
    Int J Clin Pract; 2010 Nov; 64(12):1595-8. PubMed ID: 20946266
    [No Abstract]   [Full Text] [Related]  

  • 15. ACE inhibitors are associated with a reduction in all-cause mortality versus angiotensin II receptor blockers in patients with diabetes mellitus.
    Harel Z; Silver SA
    Evid Based Med; 2014 Dec; 19(6):218. PubMed ID: 25165155
    [No Abstract]   [Full Text] [Related]  

  • 16. Experience with angiotensin II antagonists in hypertensive patients.
    Waeber B; Burnier M; Nussberger J; Brunner HR
    Clin Exp Pharmacol Physiol; 1996 Sep; 23 Suppl 3():S142-6. PubMed ID: 21143288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of Renin-Angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function.
    Meune C; Wahbi K; Duboc D; Weber S
    J Cardiovasc Pharmacol Ther; 2011; 16(3-4):368-75. PubMed ID: 21193681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on risk of atrial fibrillation before coronary artery bypass grafting.
    Johnston K; Stephens S
    Ann Pharmacother; 2012 Sep; 46(9):1239-44. PubMed ID: 22947592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison between AngII receptor antagonist and ACE inhibitor].
    Fujimi K; Urata H
    Nihon Rinsho; 2001 May; 59(5):999-1003. PubMed ID: 11392005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACP Journal Club. Review: In diabetes, ACE-Is, but not ARBs, reduce mortality and major CV events compared with placebo or active treatment.
    McCoy R; Smith S
    Ann Intern Med; 2014 Aug; 161(4):JC2. PubMed ID: 25133381
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.